Hypertrophic Obstructive Cardiomyopathy by Branson, Tiffany
Otterbein University 
Digital Commons @ Otterbein 
Nursing Student Class Projects (Formerly MSN) Student Research & Creative Work 
Fall 2014 
Hypertrophic Obstructive Cardiomyopathy 
Tiffany Branson 
Otterbein University, tiffany.branson@otterbein.edu 
Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn 
 Part of the Cardiovascular Diseases Commons, Medical Pathology Commons, and the Nursing 
Commons 
Recommended Citation 
Branson, Tiffany, "Hypertrophic Obstructive Cardiomyopathy" (2014). Nursing Student Class Projects 
(Formerly MSN). 47. 
https://digitalcommons.otterbein.edu/stu_msn/47 
This Project is brought to you for free and open access by the Student Research & Creative Work at Digital 
Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an 
authorized administrator of Digital Commons @ Otterbein. For more information, please contact 
digitalcommons07@otterbein.edu. 
Surgical Treatment Lookfordiagnosis.com (2014).  
Cardiomyopathy, Hypertrophic.  
Retrieved from 
http://lookfordiagnosis.com/mesh_i
nfo.php?term=Cardiomyopathy%2C
+Hypertrophic&lang=1 
Maron, M. S., & Maron, B. J. (2013). 
Hypertrophic cardiomyopathy. The 
Lancet, 381(9876), 242-255. 
Nishimura, R. A., & Holmes, Jr, D. R. 
(2004). Hypertrophic ObstructivE 
Cardiomyopathy. The New England 
Journal of Medicine, 350(13), 1320-
1327. 
Ommen, S. R. (2011). Hypertrophic 
Cardiomyopathy. Current Problems 
in Cardiology, 36(11), 409-453. 
Prinz, C., Farr, M., Hering, D., Horstkotte, 
       D., & Faber, L. (2011). The Diagnosis 
and Treatment of Hypertrophic 
Cardiomyopathy. Deutsches 
Ã„rzteblatt International, 108(13), 
209-215. 
South Carolina Heart Center. (2014). 
Hypertrophic Cardiomyopathy. 
Rretrieved from 
http://www.scheart.com/handler.cf
m?event=practice,template&cpid=31
08 
Spirito, P., Bruzzi, P., Badagliacca, R., 
Bernabo, P., Rapezzi, C., Autore, C., et 
al. (2009). Syncope and Risk of 
Sudden Death in Hypertrophic 
Cardiomyopathy. Circulation, 
119(13), 1703-1710. 
Spirito, P., Autore, C., Biagini, E., Quarta, 
G., Conte, M. R., Bruzzi, P., et al. 
(2009). Syncope and Risk of Sudden 
Death in Hypertrophic 
Cardiomyopathy. Circulation, 119, 
1703-1710. Retrieved September 15, 
2014, from 
http://circ.ahajournals.org/content/
119/13/1703 
Whitten, S. E. (2008). Systolic Heart 
Failure in a Patient with 
Hypertrophic obstructive 
Cardiomyopathy. Critical Care Nurse, 
28(5), 44-52. 
Yue-Cheng, H., Zuo-Cheng, L., Xi-Ming, L., 
Yuan, D. Z., Dong-Xia, J., Ying-Yi, Z., et 
al. (2013). Long-Term Follow-up 
Impact of Dual-Chamber Pacing on 
Patients with Hypertrophic 
Obstructive Cardiomyopathy. Pacing 
and Clinical Electrophysiology, 36(1), 
86-93. 
 
Hypertrophic Obstructive Cardiomyopathy 
Tiffany Branson RN, MSN 
What is Hypertrophic 
obstructive 
cardiomyopathy? 
Signs and Symptoms 
References 
     Patients with HOCM can range from 
having no symptoms at all, 
asymptomatic, to being very 
symptomatic becoming restricted. 
Some of the common symptoms of 
HOCM are:  
 
• Shortness of breath. “Most of the 
time shortness of breath 
correlates to the heart not being 
able to increase cardiac output 
upon excretion (Whitten, 2008, 
p. 47-48).  
 
• Chest pain. Decrease profusion 
in the microcoronary circulation 
plays a role in the cause of chest 
pain (Whitten, 2008, p. 47-48). .  
 
• Syncope. Syncope occurs from 
decreased cerebral perfusion 
(Whitten, 2008, p. 47-48). . 
 
• Arrhythmias. Patients with 
HOCM will sometimes have 
arrhythmias due to ventricular 
remolding, decrease cardiac 
output, microcoronary ischemia, 
and hypotension. “The most 
common types of arrhythmias 
seen with HOCM patients are 
Atrial Fibrillation (A fib), Atrial 
Flutter (A flutter), 
supraventricular tachycardia 
(SVT), ventricular tachycardia 
(VT), and heart blocks (Whitten, 
2008, p. 47-48).  
 
• The most drastic symptom of 
HOCM is sudden cardiac death 
(SCD), which is common in 
young patients and previously 
asymptomatic patients (Prinz, 
Farr, Hering, Horstkotte, & 
Faber, 2011).”  
HOCM is a disease that will require 
lifetime treatment and management. 
HOCM can be defined as thickening of the 
left ventricle with obstruction of blood 
flow. Chest pain, syncope, and shortness 
of breath are common symptom to see in 
patients with HOCM.  HOMC can be 
treated with medications and surgical 
procedures for advances cases where 
medications no longer work. “Nurses 
play a role in the knowledge of HOCM 
and how to detect problems early on” 
(Whitten, 2008 p. 52) 
Hypertrophic obstructive 
cardiomyopathy or HOCM, is a genetic 
disease that is described as hypertrophy 
or enlargement of the left ventricle 
which obstructs the blood flow to the 
body (Yue-Cheng et al., 2012).  HOCM is 
a disease that cannot be cure, but can be 
treated. One of the main goals of 
treatment is to focus on treating the 
symptoms. HOCM can be asymptomatic 
or symptomatic and can cause some 
major complications. Some of the 
complications of HOCM are arrhythmias 
and sudden cardiac death, “which is 
defined as natural death to due cardiac 
causes, heralded by abrupt loss of 
consciousness within one hour of the 
onset of acute symptoms” (Spiritio et al, 
2009, p. 1704).  
 
    “HOCM is an autosomal dominant 
disease characterized by left ventricular 
(LV) hypertrophy and left ventricular 
outflow tract obstruction” (Yue-Cheng et 
al., 2012, p. 86) in the absence of an 
underlying condition causing hypertrophy 
(Ommen, 2011). In HOCM the myocardial 
sarcomere proteins result in muscle 
disarray and fibrosis, ultimately causing 
inappropriate left ventricular hypertrophy 
(Ommen, 2011). This abnormal gene is 
causing the muscle of the heart to thicken 
The wall dividing the right and left 
ventricle becomes thick and gets in the 
way or obstructs the flow of the blood to 
the rest of the body. (Hypertrophic 
Cardiomyopathy, 2014). Because of the 
hypertrophy LV during the systolic period 
the hypertrophic interventricular septum 
protrudes into the left ventricular outflow 
tract (LVOT) and the anterior mitral valve 
leaflet moves forward, causing the LVOT to 
become narrowed or obstructed (Yue-
Cheng et al, 2012 p. 88). The obstruction 
decreases coronary perfusion pressure 
and causes decreased in cardiac output 
(Whitten, 2008,).  
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Implications for 
Nurses 
“Nurses need to understand the 
pathophysiology, management, features, 
and complications of HOCM” (Whitten, 
2008, p. 50). Nurses should talk with the 
patient regarding their medications and 
why they are on them. Nurses should 
also be aware of what HOCM is and the 
symptoms of it and what some of the 
major complications of HOCM are. When 
patients arrive to units post procedure, 
nurses should be monitoring vital signs, 
assessing the access site for signs and 
symptoms of bleeding, swelling, 
firmness and infection.  
 
 
Medical Therapy 
    Hearing a systolic murmur or holding 
an electrocardiograph (ECG) that looks 
abnormal could possible indicate that 
the patient has HOCM. Confirmation of 
HOCM is made with an 
echocardiography.  The 
echocardiography shows LV 
hypertrophy. Once the diagnosis of 
HOCM is made screening should be 
done for the immediate family for the 
autosomal dominant disorder 
(Nishimura & Holmes, 2004).  
 
    “HOCM is an autosomal dominant 
mutation of genes” (Gersh et al, 2011 p. 
2710) and genetic testing is done to 
identify any relatives that may be 
affected with this disorder. Genetic 
testing is used to determine which first-
degree family members are at risk for 
developing HOCM (Gersh et al, 2011). 
Genetic counseling can be done prior to 
the testing and will help the family 
members better understand the 
reasoning for the test, risk and benefits 
for taking the test, and can help the 
response of learning that an individual 
in the family does have a mutation of 
the gene (Gersh et al, 2011). 
Pathophysiology and Diagnosis of HOCM 
Treatment is done to relive the 
symptoms.  In HOCM the goal is to 
improve the signs and symptoms by 
“decreasing the heart rate, decreasing 
outflow obstruction, decreasing the 
oxygen demand, improving the LV 
relaxation, and improve filling 
parameters and preventing major 
complications” (Whittwen, 2008, p49). 
Initially the first medication used will be 
a beta-blocker to help slow the heart rate 
to enhance diastolic filling (Nishimura & 
Holmes, 2004). If the patient cannot 
tolerate beta-blockers, a calcium channel 
blocker like Verapamil will be used to 
help improve the symptoms of HOCM 
(Nishimura & Holmes, 2004), and 
Verapamil can also improve the function 
of the LV (Hamada, Ikeda, & Shigematsu, 
2014). “Beat-blockers are effective in 
relieving clinical symptoms, and calcium 
antagonists, such as Verapamil, are 
effective in attenuating LV diastolic 
dysfunction” (Hamada, Ikeda, & 
Shigematsu, 2014, p. 3).  Antiarrhythmic 
medications such as  Amiodarone, can be 
used in HOCM patients who have 
developed arrhythmias like A fib (Maron 
& Maron, 2013).  
 
    When pharmacological treatment is 
not enough, other options need to be 
considered. Two invasive procedures, 
surgical myectomy and percutaneous 
transluminal septal myocardial ablation 
(PTSMA), can be done to patients where 
medication is not working. “Surgical 
myectomy involves excision of a 
rectangular part of the thickened 
subaortic septum. Surgical myectomy 
ameliorates signs and symptoms in about 
70% of patients” (Whitten, 2008, p. 50). 
PTSMA was introduced in 1995 as an 
alternative to myectomy and has been 
shown to reduce the LVOT obstruction 
and associated symptoms” (Jensen et at, 
2011 p256). “PTSMA involves injecting 
ethanol into one or more the septal 
perforator arteries, producing a 
controlled infarction of the myocardial 
septum. A successful PTSMA results in 
septal thinning with reduction in the 
LVOT obstruction” (Whitten, 2008, p. 
50). Between the two procedures 
surgical myectomy is the treatment of 
choice with HOCM patients. PTSMA is 
recommended for older patients or 
patients that absolutely do not want to 
have surgery (Maron & Maron, 2013).  
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